Advocacy intelligence hub — real-time data for patient organizations
Apellis Pharmaceuticals, Inc. — PHASE2, PHASE3
Otsuka Pharmaceutical Development & Commercialization, Inc. — PHASE1
The Hospital for Sick Children — PHASE3
Assistance Publique - Hôpitaux de Paris
Mario Negri Institute for Pharmacological Research
Duke University — PHASE2
Christoph Aufricht
Northwell Health — NA
Dimerix Bioscience Pty Ltd — PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Hereditary steroid-resistant nephrotic syndrome news →
William A Gahl, M.D.
National Human Genome Research Institute (NHGRI)
📍 Bethesda, Maryland
Gerald B Appel, MD, M.D
Columbia University
📍 NEW YORK, NY
Fernando Fervenza, MD, M.D
Mayo Clinic
📍 ROCHESTER, MN
Radko Komers, MD, PhD, M.D
Travere Therapeutics, Inc.
📍 PORTLAND, OR
Giuseppe Remuzzi, MD
Istituto Di Ricerche Farmacologiche Mario Negri
Yasar Caliskan, MD, MD
Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine
📍 NASHVILLE, TN
View all Hereditary steroid-resistant nephrotic syndrome specialists →